CervoMed to Participate in the Canaccord Genuity 45th Annual Growth Conference

Core Insights - CervoMed Inc. is participating in the CG 45 Annual Growth Conference from August 12 to August 14, 2025, where management will engage in a fireside chat and one-on-one investor meetings [1][2] Company Overview - CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders [3] - The company is developing neflamapimod, an investigational orally administered small molecule that inhibits p38 mitogen-activated protein kinase alpha [3] - Neflamapimod aims to address synaptic dysfunction associated with neurodegenerative processes in disorders such as Dementia with Lewy Bodies (DLB) [3] - Currently, neflamapimod is being evaluated in a Phase 2b trial for patients with DLB [3]